The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the large unmet medical need currently unattainable from current therapeutic approaches. As the field of bioconjugation develops, and the recent spate of antibody-drug conjugates (ADCs) approvals continues, the resulting knock-on effects for delivering a wider range of bioconjugated molecules will also continue to expand in utility.
Authors: Mark Frigerio, Ph.D* and Fuan Kang, Ph.D.
Corresponding Author: Mark Frigerio, Ph.D., Vice President, Design and Development, Abzena, Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom +44 1223 903498 E-mail: Mark.Frigerio@abzena.com
Key terms: ADC, bioconjugation, therapeutic effect, manufacturing, oligonucleotides
Published In: ADC Review| Journal of Antibody-drug Conjugates
How to cite:
Frigerio M, Kang F. Addressing the Challenges of Bioconjugate Medicines – J. ADC. April 8, 2020. DOI: 10.14229/jadc.2020.04.08.001.
Last Editorial Review: April 8, 2020
- Original Manuscript Received March 23, 2020
- Review results received April 1, 2020
- Manuscript accepted for publication April 6, 2020